Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (6357)	1/20/1999 12:31:00 AM
From: Miljenko Zuanic	Respond to of 9719

V1: I agree 1000% that cash reserve is first condition for bt comps investment at many investors house. Also, I will not invest in company (at development stage) if there is not at least 6Q cash and/or company is not in position to rise cash at affordable condition. (For instance, last CBST finance was terrible because of the company position at that time) CELG does not have cash for next Q, so new finance round is must. Period. They can reduce or postpone for while new T and other candidates clinical trials, but to stay competitive and on market they have to proceed rapidly with SelCids, IMIDs and (+)-Ritalin trials. There is very little room for mistake, so I am more worry about partner for any of this program than for cash. Some cash will come from T sales (to support new T trials), but no new finance can be sufficient for SelCIDs and IMIDs development. This two programs (with Ritalin) is where should come future potential. I see cash I survival source until they secure deal, so it should not be large and dilutive, imo. I may be wrong, but it is my gut filling. Miljenko